A
911.84
-8.10 (-0.88%)
| Penutupan Terdahulu | 919.94 |
| Buka | 914.19 |
| Jumlah Dagangan | 163,090 |
| Purata Dagangan (3B) | 341,988 |
| Modal Pasaran | 56,985,411,584 |
| Harga / Pendapatan (P/E TTM) | 40.45 |
| Harga / Pendapatan (P/E Ke hadapan) | 35.84 |
| Harga / Jualan (P/S) | 13.34 |
| Harga / Buku (P/B) | 7.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Jul 2026 |
| Margin Keuntungan | 40.26% |
| Margin Operasi (TTM) | 17.50% |
| EPS Cair (TTM) | 16.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 95.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.71% |
| Nisbah Semasa (MRQ) | 7.29 |
| Aliran Tunai Operasi (OCF TTM) | -82.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.39 M |
| Pulangan Atas Aset (ROA TTM) | -0.21% |
| Pulangan Atas Ekuiti (ROE TTM) | 17.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | argenx SE | Bercampur | Menaik |
AISkor Stockmoo
0.8
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.83 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 55.54% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sands Capital Management, Llc | 31 Mar 2026 | 340,285 |
| Bellevue Group Ag | 31 Mar 2026 | 313,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |